SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 6, 2020
Avita Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
|28159 Avenue Stanford, Suite 220, Valencia, CA 91355||661.367.9170|
|(Address of principal executive offices, including Zip Code)||(Registrants telephone number, including area code)|
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
|Common Stock, par value $0.0001 per share||RCEL||The Nasdaq Stock Market LLC|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|Item 5.02|| |
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On September 6, 2020, Damien McDonald notified the Board of Directors that he will not stand for re-election as a Director at the Companys upcoming 2020 annual meeting of stockholders. Mr. McDonalds departure did not result from any disagreements between himself and the Company on any matter concerning its operations, policies or practices. Mr. McDonald will continue to serve as a Director and on the Companys Audit Committee until the expiration of his current term at the 2020 annual meeting of stockholders.
Pursuant to the requirements of the Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|AVITA THERAPEUTICS, INC.|
|Date: September 9, 2020|
|Name: David McIntyre|
|Title: Chief Financial Officer|